A year in review: Real world evidence, functional monitoring and emerging therapeutics in 2021
Year: 2022
Type: review
Abstract: In the year 2021 the SARS-CoV-2 pandemic has impacted us all, including people with cystic fibrosis (PwCF) and health care providers. International epidemiology studies have improved our understanding of the clinical sequalae of SARS-CoV-2 in CF. The European data registry reported on 130 PwCF (adults and children) with confirmed SARS-CoV-2 between February and June 2020 [1]. Overall, the incidence of infection was 2.70 per 1000 in PwCF which was greater compared to age-matched controls in the general population, although this figure may reflect more frequent testing in the Cystic Fibrosis (CF) population.
Source: Journal of Cystic Fibrosis
Authors: H.L. Barr, T. Bihouee, A.M. Zwitserloot
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,700
OpenAlex ID: W4221028541
